信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

交易中 06-23 15:57:02 EDT

4.05

+0.06

+1.38%

最高4.09	最低3.97	成交量13.88万
今开3.97	昨收3.99	日振幅3.01%
总市值1.94亿	流通市值1.38亿	总股本4,788万
成交额56.20万	换手率0.41%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":4.045,"timestamp":1782244598256,"preClose":3.99,"halted":0,"volume":138829,"delay":0,"changeRate":0.013784461152882134,"floatShares":34233044,"shares":47884104,"eps":0.209971,"marketStatus":"交易中","change":0.055,"latestTime":"06-23 15:57:02 EDT","open":3.97,"high":4.09,"low":3.97,"amount":562041.9873919999,"amplitude":0.030075,"askPrice":4.05,"askSize":961,"bidPrice":4.04,"bidSize":816,"shortable":3,"etf":0,"ttmEps":0.209971,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1782244800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":3.99,"dividendRate":0.044499,"postHourTrading":{"tag":"盘后","latestPrice":3.99,"preClose":3.99,"latestTime":"19:58 EDT","volume":8580,"amount":34233.207,"timestamp":1782172735910,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.569513,"impliedVol":1.6493,"impliedVolPercentile":0.7689},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2645097981","title":"轩竹生物-B(02575)：安奈拉唑钠新适应症根除幽门螺杆菌之III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2645097981","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645097981?lang=zh_cn&edition=full","pubTime":"2026-06-21 18:11","pubTimestamp":1782036715,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，团自主研发的创新药安奈拉唑钠肠溶片用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌之III期临床研究，近日已成功完成首例患者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。本次Hp根除适应症III期临床研究于2026年4月获中国国家药品监督管理局药品审评中心批准开展后，迅速完成首例患者入组，充分彰显公司临床开发团队的高效执行能力，亦标志该项目正式进入临床执行关键阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1191","02575","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644777227","title":"【券商聚焦】西南证券：英硅智能(03696)核心管线III期临床启动 若成功上市有望成颠覆性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2644777227","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644777227?lang=zh_cn&edition=full","pubTime":"2026-06-18 14:22","pubTimestamp":1781763776,"startTime":"0","endTime":"0","summary":"金吾财讯 | 西南证券发布研报指，英硅智能 于2026年6月13日召开核心管线Rentosertib用于治疗特发性肺纤维化的III期临床试验研究者会议。Rentosertib是全球首款完全由生成式AI发现并完成IIa期临床的候选药物。若成功上市，有望成为颠覆性疗法。主要风险包括创新药研发和商业化不及预期、竞争加剧、行业政策变化。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984105","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","BK0188","BK0183","III","BK0028","BK1141","03696","BK0012","IPOS","600369","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642264255","title":"40亿美元买来的AI药物，III期头对头打败BMS，预计明年上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2642264255","media":"智药局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642264255?lang=zh_cn&edition=full","pubTime":"2026-06-12 18:03","pubTimestamp":1781258580,"startTime":"0","endTime":"0","summary":"一款AI药物，III期实验成功！昨晚，武田公布了这款TYK2药物的最新III期临床信息。数据显示，该药物头对头疗效直接完胜BMS同靶点药物Sotyktu！武田计划在2027年上半年，将zasocitinib正式推向市场。由此，Sotyktu成为全球首款获批上市的TYK2抑制剂。目前该药物已经以1亿元首付款成功对外授权。这是中国率先由AI辅助设计、进入III期确证性临床的小分子药物。III期试验计划在中国招募约750名超重或肥胖受试者，进行52周评估，预计2028年底或2029年上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-12/doc-iniccwvp3522336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","BMS","III","ARTY","IPOS","CHAT","AGIX","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237531","title":"天辰生物-B(01779)：LP-003针对季节性过敏性鼻炎适应症的III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237531","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642237531?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:16","pubTimestamp":1781216203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，LP-003针对季节性过敏性鼻炎的III期临床试验已达到预先设定的主要终点，且该等结果在统计学及临床方面均具有高度重要性。LP-003针对季节性过敏性鼻炎适应症的III期临床试验是一项在中国开展的多中心、随机、双盲、安慰剂对照的III期临床研究，旨在比较LP-003与安慰剂治疗经标准治疗控制不佳的中重度季节性过敏性鼻炎的效果。主要排除标准为患有季节性过敏性鼻炎以外的合并症的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2642842817","title":"康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)一线治疗HER2阳性晚期乳腺癌的III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642842817","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642842817?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:05","pubTimestamp":1781089518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛用于人类表皮生长因子受体2阳性晚期乳腺癌一线治疗的III期临床研究，经独立数据监察委员会评估，成功达到预先设定的主要终点无进展生存期，结果具有显著的统计学和临床双重意义。曲妥珠单抗联合帕妥珠单抗和多西他赛目前仍是国内外HER2+晚期乳腺癌一线治疗的首选方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4134","09966","BK1574","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641820344","title":"富达国民信息服务公司(FIS)盘前涨1.59% 联合Fuse推出针对美加汽车贷款传统痛点的解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2641820344","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641820344?lang=zh_cn&edition=full","pubTime":"2026-06-08 21:20","pubTimestamp":1780924829,"startTime":"0","endTime":"0","summary":"金吾财讯 | 富达国民信息服务公司 盘前小幅走高，最新报41.60美元，涨幅1.59%，盘前成交额1.92亿美元。消息面上，该公司新近宣布已与云原生贷款解决方案提供商 Fuse 达成战略联盟。双方将针对美国和加拿大市场的间接汽车及设备贷款机构，联合推出一套现代化的端到端贷款发放解决方案，旨在解决传统系统决策滞后、人工承保繁琐等痛点，帮助贷款机构在激烈的市场竞争中赢回份额。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301278","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0077335932.USD","LU0661504455.SGD","LU1668664300.SGD","LU0310800965.SGD","BK4106","LU0738911758.USD","LU2133065610.SGD","LU0949170772.SGD","LU2279689827.SGD","III","LU1732800096.USD","LU0795875086.SGD","BK4581","LU1046421795.USD","LU2360107671.USD","LU1732799900.SGD","LU0128525689.USD","BK4588","LU0006061336.USD","LU1267930227.SGD","LU0052756011.USD","LU0912757837.SGD","LU2347655156.SGD","LU2347655073.USD","LU0162691827.USD","LU0072461881.USD","BK4134","BK4585","BK4227","LU0795875169.SGD","FIS","LU0726765562.USD","LU1823568750.SGD","LU1861217088.USD","LU1861220207.SGD","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641045171","title":"百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2641045171","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641045171?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:36","pubTimestamp":1780904174,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司的全资子公司 SystImmune,Inc.近日收到美国食品药品监督管理局的通知， BL-M14D1联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请已获得FDA许可。BL-M14D1与iza-bren 共享同一小分子技术平台，公司拥有其完整的全球权益。本次BL-M14D1的III期临床研究获得FDA的IND许可，将进一步推进公司业务和产品国际化布局的进程，对公司近期业绩不会产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","LU1815336091.USD","BK0239","02615","BL","III","LU0757428866.USD","BK4023","91194","LABU","BK4585","688506","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640197152","title":"依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2640197152","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640197152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:52","pubTimestamp":1780573920,"startTime":"0","endTime":"0","summary":"6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760581427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK4134","02615","BL","LU1815336091.USD","III","BK4023","BK0239","LU0757428866.USD","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640935521","title":"港股异动 | 开拓药业-B(09939)涨超10% KX-826 III期数据亮相WCHR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640935521","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640935521?lang=zh_cn&edition=full","pubTime":"2026-06-01 14:12","pubTimestamp":1780294340,"startTime":"0","endTime":"0","summary":"消息面上，6月1日，开拓药业宣布，自主研发、潜在同类首创的KX-826于2026年5月28日至31日在韩国首尔举行的第14届世界毛发研究大会上公布了两项重要临床研究数据。整体结果显示，KX-826在治疗脱发患者中展现出优异的有效性和安全性。该项临床观察试验由江蕾微教授等主导完成，为未来开展KX-826与米诺地尔联合疗法的III期临床试验提供了充分依据。公司表示目前正在积极推动KX-826的上市许可申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9713d282da6c79556626d0cd0f68b89d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1515","BK4134","III","BK4585","BK1161","BK1574","VXUS","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981528","title":"康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)新辅助治疗BC的III期临床研究结果于2026 ASCO年会以LBA口头报告形式呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981528","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981528?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:18","pubTimestamp":1780273113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团附属公司津曼特生物合作开发的安尼妥单抗联合注射用多西他赛新辅助治疗HER2+ BC的III期临床研究的显著性结果已于2026 ASCO年会以LBA口头报告形式呈列。KN026-004是一项随机、对照、开放、多中心III期临床研究，旨在评估安尼妥单抗联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在早期及局部晚期HER2+ BC新辅助治疗中的疗效与安全性，主要终点为由BIRC评估的 tpCR。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BC","III","09966","BK1574","BK4190","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640813439","title":"石药集团(01093)：KN026联合HB1801新辅助治疗HER2阳性乳腺癌的III期临床研究结果于2026年ASCO年会以LBA口头报告形式呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640813439","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640813439?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:13","pubTimestamp":1780272820,"startTime":"0","endTime":"0","summary":"Neo-Healer是一项随机、对照、开放标签、多中心的III期临床试验，旨在比较安尼妥单抗联合HB1801±卡铂与标准THP±卡铂方案新辅助治疗早期和局部晚期HER2阳性乳腺癌患者中的有效性与安全性。研究结果表明，安尼妥单抗联合HB1801±卡铂方案，相比现有标准双重HER2阻断联合化疗方案显著提升了tpCR率，且整体安全性可控，有望成为HER2阳性早期或局部晚期乳腺癌新辅助治疗的全新标准疗法，为这一患者人群带来更有效的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1152091754.HKD","BK1515","LU1813983027.USD","LU0501845795.SGD","LU2039709279.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","IE0008368742.USD","LU1226288253.USD","LU1226287529.USD","SG9999004220.SGD","BK1521","LU1226287792.SGD","LU1226288170.HKD","III","LU0067412154.USD","LU1008478684.HKD","LU1328277881.USD","LU0314109678.HKD","BK1191","LU1226287875.USD","LU1993786604.SGD","LU0315179316.USD","LU0326950275.SGD","LU0880133367.SGD","HK0000165453.HKD","LU0140636845.USD","IE00BZ08YR35.GBP","BK4134","IE00BZ08YT58.USD","LU1960683339.HKD","LU1807302812.USD","01093","LU0072913022.USD","IE00B5MMRT66.SGD","IE0008369823.USD","LU1951186391.HKD","LU1152091168.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989899","title":"中国生物制药(01177)：贝莫苏拜单抗联合安罗替尼一线治疗非鳞状非小细胞肺癌于2026 ASCO公布III期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989899","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640989899?lang=zh_cn&edition=full","pubTime":"2026-06-01 06:58","pubTimestamp":1780268296,"startTime":"0","endTime":"0","summary":"这是继鳞状非小细胞肺癌之后，贝莫苏拜单抗联合安罗替尼在头对头III期临床研究中再次证实优效于替雷利珠单抗联合标准化疗方案，并成为全球首个在非鳞状非小细胞肺癌一线治疗中，相较于“免疫检查点抑制剂联合化疗”取得阳性结果的III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01177","BK1521","IE00BZ08YT58.USD","III","BK1589","BK1515","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK4134","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640986039","title":"开拓药业-B(09939)：KX-826于WCHR 2026公布治疗雄激素脱发的III期临床试验及联合治疗研究数据，并获选杰出海报","url":"https://stock-news.laohu8.com/highlight/detail?id=2640986039","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640986039?lang=zh_cn&edition=full","pubTime":"2026-06-01 06:41","pubTimestamp":1780267278,"startTime":"0","endTime":"0","summary":"整体结果显示，KX-826 在治疗脱发患者中展现出优异的有效性和安全性。与米诺地尔联合治疗中国成年男性脱发的临床观察试验研究数据。该项临床观察试验由江蕾微教授等主导完成，为未来开展KX-826与米诺地尔联合疗法的III期临床试验提供了充分依据。目前，公司正在积极推动KX-826的上市许可申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4134","BK1161","09939","BK1574","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639725276","title":"BMS多发性骨髓瘤III期数据亮眼 C4 Therapeutics受提振大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2639725276","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639725276?lang=zh_cn&edition=full","pubTime":"2026-05-30 03:49","pubTimestamp":1780084140,"startTime":"0","endTime":"0","summary":"百时美施贵宝日前公布了其在研药物美齐格米德的III期临床试验阳性数据。结果显示，该联合疗法将复发或难治性多发性骨髓瘤患者的疾病进展或死亡风险降低了52%。这一积极结果不仅推高了施贵宝的股价，也显著提振了同领域生物科技公司C4 Therapeutics的市场表现。　　在施贵宝宣布这一消息后，C4 Therapeutics股价应声大涨，盘中一度触及52周新高，最终收涨逾19%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-30/doc-inhzrera0552232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4139","LENZ","CCCC","BMS","BK4007","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639644648","title":"港股异动 | 中国生物制药(01177)涨超4% 与GSK合作的Bepirovirsen将于EASL 2026公布两项III期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639644648","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639644648?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:33","pubTimestamp":1780036423,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超4%，截至发稿，涨3.95%，报5港元，成交额4.28亿港元。消息面上，5月29日，中国生物制药发布公告，本集团附属公司正大天晴药业集团股份有限公司与葛兰素史克合作的Bepirovirsen，已公布其用于治疗慢性乙型肝炎的积极关键数据。Bepirovirsen目前正在接受中国、美国、欧洲、日本监管机构的审评审批。GSK预计2027年上半年收到中国国家药品监督管理局的监管决定，目前上市准备工作正在进行中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4588","GSK.UK","BK1191","III","GSK","LU1829250122.USD","IE00BZ08YS42.EUR","BK4134","IE00BZ08YT58.USD","HK0000165453.HKD","BK1521","GSKH","BK4007","VXUS","IE00BZ08YR35.GBP","BK4585","01177","BK4532","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639648279","title":"港股异动 | 德琪医药-B(06996)涨超5% ATG-022 ADC治疗相关胃腺癌关键性III期CLINCH-3研究获临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639648279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639648279?lang=zh_cn&edition=full","pubTime":"2026-05-29 09:53","pubTimestamp":1780019635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B涨超5%，截至发稿，涨5.33%，报4.35港元，成交额327.19万港元。消息面上，德琪医药-B发布公告，经中国国家药品监督管理局(药监局)药品审评中心审评，本公司已获药审中心核准同意开展关于ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部腺癌的关键性III期CLINCH-3研究。本集团无法保证ATG-022最终将成功开发及上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK4080","BK4588","BK4134","ADC","BK1191","BK1583","VXUS","III","BK1574","BK4585","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639143996","title":"中国生物制药(01177)：BEPIROVIRSEN于EASL 2026公布两项III期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639143996","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639143996?lang=zh_cn&edition=full","pubTime":"2026-05-29 06:23","pubTimestamp":1780007004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团附属公司正大天晴药业集团股份有限公司与葛兰素史克合作的bepirovirsen，已公布其用于治疗慢性乙型肝炎的积极关键数据。HBsAg的下降还与89%的肝癌和62%的全因死亡风险降低有关。GSK预计2027年上半年收到中国国家药品监督管理局的监管决定，目前上市准备工作正在进行中。该疾病每年约造成110万人死亡，并导致约56%的全球肝癌病例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1521","01177","III","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1589","IE00BZ08YT58.USD","BK1191","BK1515","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638632546","title":"德琪医药-B(06996)：ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部(GEJ)腺癌的关键性III期CLINCH-3研究获中国临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2638632546","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638632546?lang=zh_cn&edition=full","pubTime":"2026-05-28 07:27","pubTimestamp":1779924430,"startTime":"0","endTime":"0","summary":"作为一项关键注册研究，CLINCH-3旨在支持ATG-022作为单药疗法治疗CLDN18.2+晚期胃癌或胃食管结合部腺癌的未来上市许可申请。本集团无法保证ATG-022最终将成功开发及上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","III","06996","BK1574","BK1191","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638681039","title":"核心III期数据进入倒计时，Vistagen将出席Jefferies全球医疗保健年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2638681039","media":"环球市场播报","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638681039?lang=zh_cn&edition=full","pubTime":"2026-05-27 23:28","pubTimestamp":1779895680,"startTime":"0","endTime":"0","summary":"专注于开发新型鼻内给药神经科学药物的Vistagen宣布，公司将出席于2026年6月2日至4日在纽约举行的Jefferies全球医疗保健年会。会议期间，公司管理层将与机构投资者进行一对一交流，介绍其创新的pherine候选药物管线的最新进展。　　Vistagen的先导候选药物fasedienol正处于美国注册导向的III期临床开发阶段，用于社交焦虑症的急性治疗。Vistagen认为，若其中任何一项III期试验成功，连同PALISADE-2的积极结果，可能构成提交新药上市申请所需的有效性实质证据。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzkfve8244142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","XBI","BK4585","BK4134","BK4581","BK4550","XLV","LABU","VHT","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638832606","title":"上海医药：截至2026年第一季度B001项目用于治疗视神经脊髓炎（NMOSD）的III期临床试验主研究（RCP）已完成揭盲","url":"https://stock-news.laohu8.com/highlight/detail?id=2638832606","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638832606?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:32","pubTimestamp":1779885120,"startTime":"0","endTime":"0","summary":"证券日报网5月27日讯，上海医药在接受调研者提问时表示，截至2026年第一季度，B001项目用于治疗视神经脊髓炎(NMOSD)的III期临床试验主研究(RCP)已完成揭盲。研究结果显示，B001较安慰剂可显著降低AQP4-IGG阳性NMOSD的复发风险；并且B001较已获批同类药物具备更好的安全性，输液相关不良反应、感染相关不良反应、免疫球蛋白降低和血液学相关不良反应的发生率均更低。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0097","BK0188","02607","BK0175","BK0196","III","BK1197","BK0099","601607","BK0183","BK0209","BK0012","BK0020","BK0028","BK4134","BK0187","BK0184"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.1014},{"period":"3month","weight":0.0127},{"period":"6month","weight":-0.3272},{"period":"1year","weight":-0.1231},{"period":"ytd","weight":-0.3097}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.1396},{"period":"6month","weight":0.0782},{"period":"1year","weight":0.2526},{"period":"ytd","weight":0.0916}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.004642},{"month":3,"riseRate":0.315789,"avgChangeRate":0.030463},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.00444},{"month":5,"riseRate":0.368421,"avgChangeRate":-0.021525},{"month":6,"riseRate":0.473684,"avgChangeRate":0.008558},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}